Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...

The $2.2 billion deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...